@oncoalert.bsky.socialDAY Two | OncoAlert at #GUARDSymposium2026 🇪🇸
🧬 How do we break through the IO + TKI plateau in kidney cancer?
Dr. Guillermo de Velasco 🇪🇸 from Hospital Universitario 12 de Octubre, Madrid, maps four emerging strategies in advanced #RCC — HIF-2α inhibition, T-cell engagers/CAR-T
@oncoalert.bsky.socialDAY TWO | OncoAlert at #GUARDSymposium2026 🇪🇸
🧬 Does every patient with HRR-mutated prostate cancer need a PARP inhibitor plus ARPI — and does which PARPi you choose matter?
Dr. Charles Ryan 🇺🇸 from Memorial Sloan Kettering Cancer Center, New York, delivers a keynote lecture on PARP inhibitor mgt.
@oncoalert.bsky.socialDAY THREE | OncoAlert at #GUARDSymposium2026 🇪🇸
🧬 What comes after enfortumab vedotin in urothelial cancer?
Dr. Jonathan E. Rosenberg 🇺🇸 from Memorial Sloan Kettering Cancer Center, New York, looks ahead to the next wave of ADCs and the biomarkers that will guide their use in #UrothelialCarcinoma 🔬
@oncoalert.bsky.socialDAY THREE | OncoAlert at #GUARDSymposium2026 🇪🇸
🧬 With no randomised evidence in second line, how should clinicians sequence therapy after EV+pembrolizumab in advanced bladder cancer?
Dr. Urbano Anido 🇪🇸 from Complexo Hospitalario Universitario de Santiago
@oncoalert.bsky.socialDAY 3 | OncoAlert at #GUARDSymposium2026 🇪🇸
🧬 Can we safely de-escalate perioperative therapy in muscle-invasive bladder cancer?
Dr. Andrea Necchi 🇮🇹 reviews the evolving standard of care for #MIBC — from sandwich (neoadjuvant + adjuvant) immunotherapy to next-generation bladder-sparing strategies
@oncoalert.bsky.socialDAY THREE | OncoAlert at #GUARDSymposium2026 🇪🇸
🧬 Is it finally time for ctDNA to guide treatment decisions in bladder cancer?
Dr. Sara Coca Membribes 🇬🇧 from Barts Cancer Institute, London, walks through the full biomarker landscape shaping therapy in #BladderCancer
@oncoalert.bsky.social🚨 DAY 2 | #GUARDSymposium2026 Coverage by OncoAlert
After progression, what's the right next line—TKI, IO rechallenge, or a HIF-2a combination? The evidence isn't equal across options. 🧭
At #GUARDSymposium2026, Dr. Javier Molina 🇪🇸, Servicio de Oncología Médica, Hospital Universitario Ramón y Cajal
@oncoalert.bsky.social🚨 DAY 2| #GUARDSymposium2026 Coverage by OncoAlert
CAIX or PSMA—which molecular PET target actually changes staging and treatment selection in clear-cell RCC? 🧬
At #GUARDSymposium2026, Dra. Andrea Luna Mass 🇩🇪, Nuclear Medicine, University Hospital Carl Gustav Carus, Germany
@oncoalert.bsky.social🚨 DAY 2/| #GUARDSymposium2026 Coverage by OncoAlert
Adjuvant pembrolizumab is now standard of care in high-risk RCC—so how do we build on it, and who should get belzutifan on top?
#GUARDSymposium2026, Dr. Roberto Iacovelli 🇮🇹, Servicio de Oncología Médica, Policlinico Universitario Agostino Gemelli
@oncoalert.bsky.social🚨 Day One at #GUARDSymposium2026 | OncoAlert Coverage
🧬 Can machine learning help us understand metastatic risk in prostate cancer?
Sonia Macía 🇪🇸 presents MET-score—an explainable machine-learning approach using transcriptomic data to model metastatic risk in #ProstateCancer
@oncoalert.bsky.social🚨 DAY 2 | #GUARDSymposium2026 Coverage by OncoAlert
PSMA-targeted radioligand therapy has transformed mCRPC care—so what does implementation look like as the next wave of trials arrives? ☢️
At #GUARDSymposium2026, Dr. David Kersting 🇩🇪, Essen University Hospital, Germany
@oncoalert.bsky.social🚨 DAY TWO | OncoAlert at #GUARDSymposium2026
🎯 Oligometastatic mHSPC is entering a new imaging era.
Dr. Nicholas James 🇬🇧 , The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, Sutton, UK, takes on a key clinical question:
@oncoalert.bsky.social🚨 DAY 1 | #GUARDSymposium2026 Coverage by OncoAlert
Can PSMA PET/CT redefine staging in high-risk localized #ProstateCancer —or are there still blind spots we can’t ignore? 🔬
At #GUARDSymposium2026, Dra. Iratxe Fernández 🇪🇸, Servicio de Medicina Nuclear, Hospital Universitario de Cruces, Bilbao
@oncoalert.bsky.social🚨 DAY ONE | OncoAlert at #GUARDSymposium2026 🇪🇸
🧬 What drives prostate cancer to become more aggressive?
Dr. Arkaitz Carracedo 🇪🇸 from CIC bioGUNE, Bilbao, presents two studies exploring the molecular drivers underlying the acquisition of aggressive features in #ProstateCancer
@oncoalert.bsky.social🚨 DAY 1 | #GUARDSymposium2026 🇪🇸
Can SBRT redefine radiotherapy for high-risk prostate cancer?
At #GUARDSymposium2026, Dr. Giulia Marvaso🇮🇹 from Istituto Europeo di Oncologia and Università degli Studi di Milano explores the evolving role of SBRT in high-risk prostate cancer.
@oncoalert.bsky.social🚨 DAY 1 | #GUARDSymposium2026 Coverage by OncoAlert
What if early salvage radiotherapy can deliver the same oncologic control as adjuvant RT—with fewer side effects?
Dr. Luca Nicosia🇮🇹 discusses early salvage RT ☢️ after radical prostatectomy in high-risk localized or locally adv #ProstateCancer
